Vaccinex Inc USD0.0001

Sell:$0.70Buy:$0.70$0.22 (45.52%)

Prices delayed by at least 15 minutes
Sell:$0.70
Buy:$0.70
Change:$0.22 (45.52%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.70
Buy:$0.70
Change:$0.22 (45.52%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. It also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.

Key people

Albert D. Friedberg
Chairman of the Board
Maurice Zauderer
President, Chief Executive Officer, Director
Jill Sanchez
Chief Financial Officer
Elizabeth E. Evans
Chief Operating Officer, Senior Vice President - Translational Medicine and Discovery
Ernest S. Smith
Senior Vice President - Research, Chief Scientific Officer
Jacob B. Frieberg
Independent Director
Click to see more

Key facts

  • Shares in issue
    2.68m
  • EPIC
    VCNX
  • ISIN
    US9186403013
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $1.34m
  • Employees
    23
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview of the company, currency, shares in issue, EPIC, location, exchange, index, website, Data sourced by LSEG. Objective, Costs, Fee Structure, Key facts including Benchmark, Gross gearing are provided by MorningStar.